In the field of medicine, Infectious Pulmonary Diseases (CTD-ILD) associated with fibrosis are a more difficult category, posing a serious threat to the health of many patients. Understanding the optimal treatment of fibrosis CTD-ILD is of great importance both for the patient himself and for the medical community as a whole.
Fibrogenic CTD-ILD is an inter-senso-pulmonary disease caused by systematic self-immunological disease and lung stress, the pathology of which is characterized by inter-pulmonary fibrosis. This fibrosis leads to a gradual hardening and thickening of the lung tissue, which greatly affects normal ventilation and aerobics in the lung. Patients often suffer from aggravated respiratory difficulties, coughs and inactivity, and the quality of life is severely reduced or even life-threatening.
For fibrotic CTD-ILD treatment, early diagnosis is a critical first step. By means of detailed medical history inquiries, medical examinations, self-antibody tests, high-resolution chest CT scans and lung function checks, it is possible to detect the disease at an early stage and to buy valuable time for subsequent treatment. Drug treatment is central to the treatment approach. Traditional immunosuppressants, such as cyclophosphate, sulfur, etc., can, to some extent, inhibit the over-activation of the immune system and thus slow the process of lung fibrosis. However, the efficacy of these drugs is limited and may be accompanied by varying degrees of side effects.
In recent years, new types of anti-fibrous drugs have emerged as a result of further medical research, giving new hope to patients. Nidanib, for example, can cut off multiple cell signals involved in the fibrosis process and effectively reduce progress in lung fibrosis.
In addition to drug treatment, integrated treatment measures are indispensable. Oxygen therapy has an immediate effect on the improvement of a patient ‘ s aerobic deficiency, which can alleviate respiratory difficulties and increase the patient ‘ s motor resilience. Pulmonary rehabilitation training is also essential for patients with more severe conditions. Through a combination of a combination of respiratory activity, physical training, nutritional support and psychological counselling, patients can be helped to recover part of their lung function, increase the resilience of their bodies, improve their ability to provide for themselves while reducing their psychological burden and building confidence in overcoming disease.
Throughout the treatment, it is particularly important to manage the patient ‘ s entire course. Patients are required to visit the hospital regularly for review, including for chest CT, lung function, etc., so that the doctor can keep abreast of the changes and adjust the treatment programme. At the same time, patients themselves must actively cooperate with the treatment and maintain good living habits, such as cessation of smoking and alcohol, balanced diet, adequate exercise and prevention of infection. Fibrotic CTD-ILD treatment was a long and difficult battle, but it was not hopeless. Through early diagnosis, rational use of medication, integrated treatment and comprehensive management, we can light the light of hope for the patient, slow the progress of the disease, improve the quality of life and regenerate the patient in the fight against the disease.
